THE CHROMOSOME | Clinical Content Series
Non Alcoholic Fatty Liver Disease
Back to Case Studies ArchiveCase Study
He was 48 years old and had been told at a routine health check that his liver enzymes were mildly elevated. His physician had asked him whether he drank alcohol. He did not, not a drop, ever, in his life. His physician had nodded, made a note, and told him to watch his diet. No further investigation had been pursued. No explanation had been offered. No follow up had been arranged.
That was three years before he came to see me.
In those three years his weight had increased by 17 kilograms. His fatigue had deepened to the point where he was struggling to complete a full working day. He had developed a persistent discomfort in his right upper abdomen that came and went without clear pattern. His liver enzymes, when I repeated them, had risen substantially from the mildly elevated levels of three years earlier. His ultrasound showed a liver that was bright and enlarged, the sonographic signature of significant fatty infiltration.
He had non alcoholic fatty liver disease. And it had been silently progressing for at least three years while he had been told to watch his diet.
This is the clinical reality of non alcoholic fatty liver disease in Pakistani men, and increasingly in Pakistani women. It is common, it is progressive, it is metabolically devastating in its downstream consequences, and it is almost universally underestimated in Pakistani clinical practice. A mildly elevated ALT is noted, alcohol is excluded as a cause, and the patient is sent home with dietary advice that addresses neither the metabolic origin of the condition nor the hormonal environment sustaining it.
The liver does not accumulate fat arbitrarily. It accumulates fat because it is being overwhelmed, by excess glucose arriving from insulin resistant peripheral tissues, by excess fructose from the refined carbohydrate diet that characterises the Pakistani dietary transition, by inflammatory signals from visceral fat that sits in direct anatomical proximity to the portal circulation, and by the disrupted hormonal milieu that the FTO gene associated metabolic profile creates from the ground up.
When I reviewed his full metabolic picture the drivers were all present and all interconnected. His insulin resistance was significant. His visceral fat was substantial and measurable on imaging. His triglycerides were elevated. His cortisol pattern was dysregulated. His thyroid conversion was impaired. His growth hormone axis showed the suppression I consistently find in patients with significant hepatic fat accumulation, because the liver is the primary site of IGF-1 production, and a fatty, inflamed liver produces IGF-1 inefficiently.
The FTO gene's influence on hepatic fat metabolism, insulin signalling, and visceral fat distribution creates a predisposition to non alcoholic fatty liver disease in Pakistani patients that is activated and accelerated by the dietary and lifestyle patterns of Pakistani urban life. I see this condition in patients in their thirties. I see it in patients who are not dramatically obese by conventional measures. I see it in patients who have been told their liver tests are only mildly abnormal and therefore not a concern. Mildly abnormal liver tests in a Pakistani patient with visceral obesity and insulin resistance are always a concern, because they are the first readable signal of a process that, left unaddressed, progresses to non alcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
We treated the metabolic origin. We reversed his insulin resistance. We reduced his visceral fat load through the comprehensive protocol. We recalibrated his cortisol and thyroid axes. We addressed his dietary pattern at the level of hepatic fat metabolism rather than simply caloric content.
Fourteen months later his liver enzymes had normalised completely. His ultrasound showed resolution of the fatty infiltration. He had lost 23 kilograms. His fatigue had resolved. The right upper abdominal discomfort had disappeared.
His liver had not simply been watched. It had been treated. There is a profound difference between those two things, and in Pakistani medicine, that difference is rarely made.
FAQs
Non alcoholic fatty liver disease is a condition of excessive fat accumulation within liver cells in the complete absence of alcohol consumption. It ranges from simple steatosis, fatty infiltration without inflammation, through non alcoholic steatohepatitis, which involves active liver cell injury and inflammation, to fibrosis and cirrhosis in advanced cases. In Pakistani adults it is significantly prevalent because the FTO gene associated predisposition to insulin resistance and visceral fat accumulation creates the precise metabolic environment in which hepatic fat accumulation is driven and sustained. The Pakistani dietary transition toward refined carbohydrates and fructose rich foods provides the substrate. The insulin resistance determines what the liver does with it.
When peripheral tissues are resistant to insulin, glucose cannot enter muscle cells efficiently and accumulates in the bloodstream instead. The liver responds to this excess circulating glucose and insulin by converting glucose into triglycerides through a process called de novo lipogenesis, essentially manufacturing fat from excess sugar. This newly synthesised fat accumulates within liver cells when the rate of production exceeds the liver's capacity to export it. Simultaneously, insulin resistance impairs the liver's ability to oxidise existing fatty acids for energy, further promoting their accumulation. The liver becomes progressively fattier not because of dietary fat intake but because of the glucose and insulin overflow driven by peripheral insulin resistance, a mechanism almost never explained to Pakistani patients receiving dietary advice for fatty liver.
The FTO gene at Chromosome 16q12.2 influences hepatic insulin sensitivity, visceral fat distribution, and the inflammatory signalling that drives liver cell injury in non alcoholic fatty liver disease. In Pakistani patients, the FTO associated metabolic profile creates a predisposition to hepatic insulin resistance that is independent of body weight, meaning Pakistani patients develop significant hepatic fat accumulation at lower degrees of overall obesity than Western populations. Research on South Asian populations consistently shows higher rates of non alcoholic fatty liver disease at lower BMI thresholds, with more rapid progression to fibrosis and more severe metabolic consequences than equivalent Western patients. Dr. Zaar identifies and treats this genetic amplification of hepatic metabolic vulnerability as a core component of every Pakistani obesity assessment.
The liver is not merely a passive victim of metabolic syndrome, it is an active hormonal organ whose dysfunction amplifies every surrounding hormonal disorder simultaneously. A fatty infiltrated liver produces IGF-1 inefficiently, worsening growth hormone axis dysfunction. It impairs thyroid hormone conversion from T4 to active T3, deepening functional hypothyroidism. It processes oestrogen and cortisol less effectively, allowing both to accumulate and drive their respective hormonal disruptions. It produces inflammatory acute phase proteins that worsen insulin resistance and suppress testosterone. And it generates excess triglycerides that impair leptin transport across the blood brain barrier, worsening central leptin resistance. In Pakistani patients with multiple hormonal disorders, the liver is almost always a contributing driver, and its restoration is essential to meaningful hormonal recovery across every axis.
The most dangerous characteristic of non alcoholic fatty liver disease is that it is almost entirely asymptomatic in its early and middle stages, the stages at which intervention is most effective. Mildly elevated liver enzymes discovered incidentally are the most common early signal and are routinely dismissed in Pakistani clinical practice once alcohol is excluded. Persistent fatigue that does not respond to sleep or rest is a common but non specific symptom. Right upper abdominal discomfort or heaviness is present in some patients but absent in many. Increasing difficulty losing weight despite dietary effort, because the fatty liver impairs metabolic hormone processing, is a metabolic signal that is never attributed to its hepatic origin. Dr. Zaar investigates liver health proactively in every Pakistani obesity patient rather than waiting for symptoms that may never arrive before significant damage has occurred.
Visceral fat sits in immediate anatomical proximity to the liver, separated only by the portal circulation that drains directly into it. The inflammatory cytokines, free fatty acids, and adipokines released continuously by visceral fat enter the liver in high concentration before reaching any other organ in the body. This direct hepatic exposure to visceral fat secretions drives liver cell inflammation, impairs insulin signalling within hepatocytes, stimulates hepatic triglyceride synthesis, and activates the fibrogenic pathways that produce liver scarring in progressive non alcoholic fatty liver disease. Reducing visceral fat is therefore not simply a cosmetic or cardiovascular intervention in Pakistani patients with fatty liver, it is the most direct and most effective anti inflammatory treatment the liver can receive.
Non alcoholic fatty liver disease in its earlier stages, simple steatosis and early steatohepatitis, is fully reversible when the metabolic drivers are addressed comprehensively. Significant visceral fat reduction produces measurable hepatic fat reduction within months. Insulin resistance reversal removes the primary driver of hepatic de novo lipogenesis. Dietary recalibration targeted specifically at fructose and refined carbohydrate reduction reduces the hepatic substrate load directly. Cortisol and thyroid normalisation restore hepatic metabolic efficiency. In Dr. Zaar's patients, complete ultrasound resolution of fatty liver is achievable in the majority of cases treated comprehensively, not through liver specific medication but through systemic metabolic restoration. The liver, unlike many other organs damaged by metabolic disease, retains a remarkable capacity for recovery when the conditions driving its damage are removed.
Untreated non alcoholic fatty liver disease follows a progression that Pakistani medicine consistently underestimates. Simple fatty infiltration progresses to steatohepatitis, active liver cell injury and inflammation, in a proportion of patients. Steatohepatitis progresses to fibrosis and then cirrhosis, irreversible structural liver damage, in those with ongoing metabolic stress, genetic predisposition, and inadequate treatment. Cirrhosis carries a significant risk of hepatocellular carcinoma, primary liver cancer, which is among the most lethal malignancies in human medicine. Pakistani patients with the FTO associated metabolic profile progress through these stages more rapidly than Western populations at equivalent degrees of obesity. The patient told to watch his diet and return in a year is not being managed conservatively. He is being managed inadequately, and the difference becomes apparent only when the damage has become irreversible.